		All patie	nts (Pre	e-Matching)		Matched patients (Post-Matching)				
	IMRT (57 Pat)		PB	Г (31 Pat)		IMF	RT (29 Pat)	PB	T (29 Pat)	
Matching variable	Pat	(%)	Pat	(%)	p-value	Pat	(%)	Pat	(%)	p-value
Diabetes mellitus					0.073*					0.76*
Yes	9	(15.8)	10	(32.2)		7	(24.1)	8	(27.6)	
No	48	(84.2)	21	(67.7)		22	(57.9)	21	(72.4)	
TUR-P					0.92*					0.55*
Yes	4	(7.0)	2	(6.5)		1	(3.4)	2	(6.9)	
No	53	(93.0)	29	(93.5)		28	(96.6)	27	(93.1)	
Risk group D'Amico					0.85†					0.35†
Low	5	(8.8)	2	(6.5)		0	(0.0)	2	(6.9)	
Intermediate	41	(71.9)	24	(77.4)		23	(79.3)	22	(75.9)	
High	11	(19.3)	5	(16.1)		6	(20.7)	5	(17.2)	
Anticoagulants					0.22*					0.58*
Yes	26	(45.6)	10	(32.3)		11	(37.9)	9	(31.0)	
No	31	(54.4)	21	(67.7)		18	(62.1)	20	(69.0)	
Prostate volume in cm ³					0.007‡					0.35‡
median (range)	61	(23 - 119)	51	(22 - 99)		53	(32 - 119)	51	(22 - 99)	

TABLE S1. Matching variables for all patients and those selected for the matched-pair analysis.

Abbreviations: Pat, patients; TUR-P, transurethral resection of the prostate; IMRT, intensity-modulated radiotherapy; PBT, proton beam therapy.

* Exact Fisher test

† χ² test

‡ Mann-Whitney U test

Item	Base	eline	3 m af	fter RT	12 m after RT		
	No	(%)	No	(%)	No	(%)	
EORTC QLQ-C30							
Functional scales							
Global health status	21	(72.4)	18	(62.1)	11	(37.9)	
Role functioning	22	(75.9)	17	(58.6)	10	(34.5)	
Emotional functioning	22	(75.9)	18	(62.1)	11	(37.9)	
Physical functioning	23	(79.3)	19	(65.5)	11	(37.9)	
Social functioning	22	(75.9)	17	(58.6)	10	(34.5)	
Cognitive functioning	22	(75.9)	18	(62.1)	10	(34.5)	
Symptom scales							
Pain	18	(62.1)	17	(58.6)	11	(37.9)	
Diarrhoea	22	(75.9)	18	(62.1)	10	(34.5)	
Fatigue	22	(75.9)	19	(65.5)	11	(37.9)	
Insomnia	22	(75.9)	19	(65.5)	11	(37.9)	
Constipation	22	(75.9)	18	(62.1)	10	(34.5)	
Nausea and vomiting	22	(75.9)	19	(65.5)	11	(37.9)	
Appetite loss	21	(72.4)	19	(65.5)	11	(37.9)	
Dyspnoea	22	(75.9)	19	(65.5)	11	(37.9)	
Financial difficulties	22	(75.9)	18	(62.1)	11	(37.9)	
EORTC QLQ-PR25							
Symptom scales							
Urinary symptoms	22	(75.9)	18	(62.1)	11	(37.9)	
Incontinence aid	11	(37.9)	16	(55.2)	11	(37.9)	
Bowel symptoms	12	(41.4)	17	(58.6)	10	(34.5)	
Hormon treatment related symptoms	11	(37.9)	17	(58.6)	10	(34.5)	
Functional scales							
Sexual activity	15	(51.7)	18	(62.1)	8	(27.6)	
Sexual functioning	4	(13.8)	2	(6.9)	2	(6.9)	

TABLE S2. Questionnaire response rates for complete pairs at different time points	TABLE S2.	Questionnaire r	esponse rates	for complete	pairs at diffe	rent time points
---	-----------	-----------------	---------------	--------------	----------------	------------------

Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; QLQ-C30, general quality of life questionnaire; QLQ-PR25, prostate-cancer specific questionnaire; RT, radiotherapy; No, number; m, months.

Side-effect	IMRT	РВТ
Early GU	One patient developed grade 3 pelvic pain 3 months after IMRT. The pain was first associated with the initial RT-induced cystitis and recorded with grade 3 because of the use of fentanyl patch. The symptoms were then most likely associated with arthrosis.	One patient presented with grade 3 obstructive symptoms and a grade 2 urinary urgency, which were associated with an increased urinary frequency of grade 3. Therefore, a bladder catheter was inserted during the treatment. The symptoms improved at the end of the treatment and the catheter could be removed. The obstructive symptoms persisted, but an improvement was achieved with the administration of alpha-blockers.
Early GI	No grade 3 side-effects	At the third treatment week, one patient showed grade 3 diarrhoea that improved after oral therapy. The same patient had episodic grade 1-2 diarrhoea until the end of the therapy and mild diarrhoea 3 months afterwards, followed by no further episodes in the long-term follow up.
Late GU	One patient with initial stage cT4 (infiltration of the bladder) presented with grade 3 obstructive symptoms around 11 months after IMRT. He was hospitalized due to a urethra stenosis and subsequently underwent to a surgical procedure of urethral expansion with improvement of the symptoms.	No grade 3 side-effects
Late GI	No grade 3 side-effects	One patient had grade 2 proctitis in combination with grade 3 rectal bleeding and was hospitalized. At the same time, the patient also had a pulmonary embolism that was originally assessed as tumor-related. Subsequently, the patient received a rectoscopy and argon-plasma coagulation therapy. Afterwards, the pulmonary embolism was associated with previous circulatory diseases and treated with medical therapy. Since hospitalization was associated with both pulmonary embolism and proctitis, this toxicity was initially recorded with grade 3. , gastrointestinal; GU, genitourinary; PBT, proton

TABLE S3. Detailed information on patients presented with grade 3 side-effects.

U, genitourinary; PBT, proton RT, intensityointestinal; G erapy; GI, ga beam therapy.

	D2% in Gy	D _{mean} in Gy	V40Gy (%)	V50Gy (%)	V60Gy (%)	V70Gy (%)	V75Gy (%)
Rectum							
PBT	74.8 ± 1.2	21.1 ± 5.0	27.1 ± 7.4	22.7 ± 6.5	15.9 ± 4.3	9.4 ± 3.0	2.5 ± 2.7
IMRT	76.0 ± 1.3	44.7 ± 4.9	55.8 ± 11.0	41.9 ± 10.5	28.3 ± 9.0	12.7 ± 5.1	5.0 ± 3.2
p-value*	<0.001	<0.001	<0.001	<0.001	<0.001	0.013	0.005
Rectal wall							
РВТ	75.3 ± 1	19.7 ± 3.4	25.8 ± 4.7	23.1 ± 4.2	18.3 ± 3.4	13.6 ± 2.8	4.2 ± 4.4
IMRT	76.7 ± 1.3	42 ± 5.4	47.8 ± 9.6	38.5 ± 8.3	29.5 ± 7.2	20.1 ± 5.8	11.1 ± 6.5
p-value*	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Bladder							
РВТ	74.8 ± 1.3	20.9 ± 10.2	30.0 ± 14.0	20.0 ± 13.1	20.0 ± 11.6	10 ± 9.1	0.0 ± 6.3
IMRT	78.1 ± 1.7	36.2 ± 9.9	43.0 ± 15.7	33.7 ± 13.0	25.6 ± 10.7	17.5 ± 8.2	11.6 ± 7.4
p-value*	<0.001	<0.001	<0.001	0.001	<0.002	<0.001	<0.001
Bladder wall							
РВТ	75.3 ± 1	23.3 ± 7.9	30.9 ± 10.8	27.7 ± 10.0	23.1 ± 8.6	17 ± 6.6	4.7 ± 6.6
IMRT	78.5 ± 1.5	35.7 ± 8.2	42.1 ± 11.9	34.6 ± 9.9	28.1 ± 8.6	21.4 ± 6.9	15.8 ± 7.6
p-value*	<0.001	<0.001	<0.001	0.006	0.016	0.010	<0.001
Bladder wall							
anterior							
PBT	60.2 ± 16.7	7.8 ± 6.2	8.7 ± 8.1	6.7 ± 7.2	4.7 ± 5.8	2.5 ± 4.2	0.7 ± 2.3
IMRT	74 ± 5.2	24.2 ± 7.3	23.6 ± 10.1	15 ± 7.3	9.9 ± 6.2	6.0 ± 5.0	3.7 ± 4.1
p-value*	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Bladder wall posterior							
PBT	75.7 ± 1.1	51.1 ± 8.3	70.2 ± 12.3	64.5 ± 12.3	54.7 ± 12.6	41.4 ± 11.4	11.9 ± 14.8
IMRT	78.8 ± 1.4	64 ± 6.6	86.4 ± 8.9	81.3 ± 10.5	72.0 ± 14.6	59.0 ± 16.8	44.0 ± 19.5
p-value*	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

TABLE S4. Comparison of dose-volume parameter (mean ± standard deviation) of organs at risk for patients treated with proton beam therapy (PBT) and intensity-modulated radiotherapy (IMRT).

Abbreviations: VxGy, relative volume receiving x Gy, Dx% dose to x % of organ volume, *Mann-Whitney U test

	D2% in Gy	D _{mean} in Gy	V40Gy (%)	V50Gy (%)	V60Gy (%)	V70Gy (%)	V75Gy (%)
Rectum							
PBT	74.8 ± 1.2	21.1 ± 5.0	27.1 ± 7.4	22.7 ± 6.5	15.9 ± 4.3	9.4 ± 3.0	2.5 ± 2.7
IMRT	72.8 ± 0.6	42.9 ± 4.5	53.3 ± 10.8	39.2 ± 10.1	24.2 ± 8.0	8.5 ± 2.8	0.0 ± 0.1
p-value*	<0.001	<0.001	<0.001	<0.001	<0.001	0.266	<0.001
Rectal wall							
РВТ	75.3 ± 1.0	19.7 ± 3.4	25.8 ± 4.7	23.1 ± 4.2	18.3 ± 3.4	13.6 ± 2.8	4.2 ± 4.4
IMRT	73.4 ± 0.6	40.3 ± 5.1	46.2 ± 9.2	36.7 ± 8.1	27.0 ± 6.9	16.7 ± 4.8	0.1 ± 0.2
p-value*	<0.001	<0.001	<0.001	<0.001	<0.001	0.009	<0.001
Bladder							
PBT	74.8 ± 1.3	20.9 ± 10.2	26.8 ± 14.0	22.9 ± 13.1	18.0 ± 11.6	11.7 ± 9.1	3.0 ± 6.3
IMRT	74.8 ± 0.8	34.7 ± 9.2	41.2 ± 15.1	31.8 ± 12.2	23.2 ± 9.8	14.6 ± 6.9	2.4 ± 2.5
p-value*	0.35	<0.001	<0.001	0.003	0.012	0.027	0.18
Bladder wall							
РВТ	75.3 ± 1.0	23.3 ± 7.9	30.9 ± 10.8	27.7 ± 10.0	23.1 ± 8.6	17.0 ± 6.6	4.7 ± 6.6
IMRT	75.2 ± 0.5	34.2 ± 7.6	40.7 ± 11.4	33.2 ± 9.4	26.1 ± 7.9	19.1 ± 6.1	3.9 ± 3.2
p-value*	0.387	<0.001	0.001	0.009	0.038	0.074	0.20
Bladder wall							
anterior							
PBT	60.2 ± 16.7	7.8 ± 6.2	8.7 ± 8.1	6.7 ± 7.2	4.7 ± 5.8	2.5 ± 4.2	0.7 ± 2.3
IMRT	70.9 ± 4.6	23.2 ± 6.9	21.8 ± 9.4	13.6 ± 7.0	8.7 ± 5.8	4.9 ± 4.6	0.9 ± 1.7
p-value*	0.003	<0.001	<0.001	<0.001	<0.001	0.004	0.030
Bladder wall posterior							
РВТ	75.7 ± 1.1	51.1 ± 8.3	70.2 ± 12.3	64.5 ± 12.3	54.7 ± 12.6	41.4 ± 11.4	11.9 ± 14.8
IMRT	75.5 ± 0.5	61.3 ± 6.3	85.6 ± 9.1	79.9 ± 11.1	68.3 ± 15.9	54.4 ± 17.1	10.8 ± 8.9
p-value*	0.69	<0.001	<0.001	<0.001	0.002	0.007	0.35

TABLE S5. Comparison of dose-volume parameter (mean ± standard deviation) of organs at risk for patients treated with proton beam therapy (PBT) and intensity-modulated radiotherapy (IMRT) for all plans after rescaling to 74 Gy.

Abbreviations: VxGy, relative volume receiving x Gy, Dx% dose to x % of organ volume, *Mann-Whitney U test

		IMRT			PBT		
Item	Mean ± SD	Median	IQR	Mean ± SD	Median	IQR	
EORTC QLQ-C30							
Global health status	61.9 ± 24.1	66.7	[50 - 83.3]	73.0 ± 21.3	83.3	[66.7 - 83.3]	
Role functioning	80.3 ± 25.9	91.7	[70.8 - 100]	93.2 ± 18.6	100.0	[100 - 100]	
Emotional functioning	76.5 ± 24.2	79.2	[66.7 - 100]	67.0 ± 29.8	75.0	[41.7 - 91.7]	
Physical functioning	80.3 ± 18.8	80.0	[70 - 96.7]	88.7 ± 18.3	100.0	[83.3 - 100]	
Social functioning	84.8 ± 21.9	100.0	[70.8 - 100]	81.1 ± 27.7	83.3	[83.3 - 100]	
Cognitive functioning	81.1 ± 20.3	83.3	[66.7 - 100]	84.1 ± 17.0	83.3	[83.3 - 100]	
Pain	21.3 ± 25.3	0.0	[0 - 45.8]	14.8 ± 27.7	0.0	[0 - 16.7]	
Diarrhoea	6.1 ± 12.9	0.0	[0 - 0]	6.1 ± 12.9	0.0	[0 - 0]	
Fatigue	26.8 ± 27.6	22.2	[0 - 41.7]	25.0 ± 21.8	22.2	[11.1 - 30.6]	
Insomnia	21.2 ± 27.6	0.0	[0 - 33.3]	27.3 ± 29.5	33.3	[0 - 33.3]	
Constipation	9.1 ± 22.9	0.0	[0 - 0]	6.1 ± 12.9	0.0	[0 - 0]	
Nausea and vomiting	0 ± 0	0.0	[0 - 0]	0.8 ± 3.5	0.0	[0 - 0]	
Appetite loss	7.9 ± 17.5	0.0	[0 - 0]	6.3 ± 22.1	0.0	[0 - 0]	
Dyspnoea	12.1 ± 25.7	0.0	[0 - 0]	10.6 ± 18.5	0.0	[0 - 25]	
Financial difficulties	10.6 ± 21	0.0	[0 - 0]	4.5 ± 20.8	0.0	[0 - 0]	
EORTC QLQ-PR25							
Urinary symptoms	24 ± 14.4	19.0	[19 - 28.6]	24.4 ± 17.2	21.4	[12.9 - 34.5]	
Incontinence aid	6.1 ± 12.9	0.0	[0 - 0]	9.1 ± 20.6	0.0	[0 - 0]	
Bowel symptoms	4.2 ± 8	0.0	[0 - 2.1]	2.8 ± 7.1	0.0	[0 - 0]	
Hormone treatment- related symptoms	9.3 ± 12	0.0	[0 - 17.8]	8.5 ± 13.4	0.0	[0 - 14.4]	
Sexual activity	65.6 ± 30.1	66.7	[41.7 - 91.7]	62.2 ± 29.5	66.7	[41.7 - 91.7]	
Sexual functioning	50.7 ± 9.7	47.2	[43.8 - 54.2]	60.4 ± 20.7	70.8	[56.3 - 75]	

TABLE S6. Baseline Quality of Life Scores according to EORTC QLQ-C30 and prostate-cancer specific QLQ-PR25 module.

Abbreviations: SD, standard deviation; IQR, interquartile range; PBRT, proton beam therapy; IMRT, intensity-modulated radiotherapy.

		IMRT			PBT		
Item	Mean ± SD	Median	IQR	Mean ± SD	Median	IQR	
Global health status	69.4 ± 16.2	66.7	[50 - 83.3]	68.5 ± 24.6	79.2	[60.4 - 83.3]	
Role functioning	86.3 ± 21.6	100.0	[83.3 - 100]	86.3 ± 23	100.0	[83.3 - 100]	
Emotional functioning	81.9 ± 24.9	91.7	[75 - 100]	78.7 ± 27.8	91.7	[56.3 - 100]	
Physical functioning	82.5 ± 14.7	86.7	[70 - 93.3]	88.4 ± 16.3	93.3	[86.7 - 100]	
Social functioning	85.3 ± 20.5	100.0	[66.7 - 100]	88.2 ± 19.6	100.0	[83.3 - 100]	
Cognitive functioning	88 ± 13.4	83.3	[83.3 - 100]	81.5 ± 24.8	83.3	[70.8 - 100]	
Pain	16.7 ± 25.6	0.0	[0 - 16.7]	15.7 ± 26.5	0.0	[0 - 33.3]	
Diarrhoea	7.4 ± 13.9	0.0	[0 - 0]	11.1 ± 22.2	0.0	[0 - 0]	
Fatigue	29.5 ± 22.5	33.3	[11.1 - 44.4]	26.3 ± 30	22.2	[0 - 38.9]	
Insomnia	28.1 ± 31.1	33.3	[0 - 50]	31.6 ± 31.5	33.3	[0 - 33.3]	
Constipation	20.4 ± 31.7	0.0	[0 - 33.3]	3.7 ± 10.5	0.0	[0 - 0]	
Nausea and vomiting	1.8 ± 5.1	0.0	[0 - 0]	2.6 ± 8.1	0.0	[0 - 0]	
Appetite loss	7 ± 17.4	0.0	[0 - 0]	3.5 ± 14.9	0.0	[0 - 0]	
Dyspnoea	10.5 ± 18.9	0.0	[0 - 16.7]	12.3 ± 27	0.0	[0 - 0]	
Financial difficulties	7.4 ± 13.9	0.0	[0 - 0]	11.1 ± 24.8	0.0	[0 - 0]	
Urinary symptoms	32.5 ± 18.7	28.6	[23.8 - 45.2]	28.4 ± 17	23.8	[14.3 - 38.1]	
Incontinence aid	20.8 ± 20	33.3	[0 - 33.3]	12.5 ± 16.1	0.0	[0 - 33.3]	
Bowel symptoms	11.8 ± 18.3	8.3	[0 - 16.7]	5.4 ± 7	0.0	[0 - 8.3]	
Hormone treatment- related symptoms	17 ± 15.4	13.3	[6.7 - 26.7]	16.9 ± 18.3	13.3	[0 - 20]	
Sexual activity	76.9 ± 26.1	83.3	[66.7 - 100]	70.4 ± 27.5	66.7	[50 - 100]	
Sexual functioning	41.7 ± 0	41.7	[41.7 - 41.7]	70.8 ± 4.2	70.8	[68.8 - 72.9]	

TABLE S7. Quality of Life Scores according to EORTC QLQ-C30 and prostate-cancer specific QLQ-PR25 3 months after radiotherapy.

Abbreviations: SD, standard deviation; IQR, interquartile range; PBRT, proton beam therapy; IMRT, intensity-modulated radiotherapy.

		IMRT			PBT		
Item	Mean ± SD	Median	IQR	Mean ± SD	Median	IQR	
EORTC QLQ-C30							
Global health status	67.4 ± 20.2	66.7	[58.3 - 83.3]	74.2 ± 20.9	83.3	[62.5 - 83.3]	
Role functioning	70 ± 25.6	66.7	[54.2 - 95.8]	85 ± 21.7	100.0	[70.8 - 100]	
Emotional functioning	64.4 ± 25.6	58.3	[41.7 - 87.5]	81.1 ± 29.5	100.0	[70.8 - 100]	
Physical functioning	73.3 ± 20.9	73.3	[63.3 - 93.3]	86.7 ± 18.2	100.0	[76.7 - 100]	
Social functioning	76.7 ± 22.6	75.0	[66.7 - 100]	90 ± 17	100.0	[87.5 - 100]	
Cognitive functioning	78.3 ± 23.6	91.7	[50 - 100]	85 ± 29.3	100.0	[83.3 - 100]	
Pain	30.3 ± 32.4	33.3	[0 - 33.3]	21.2 ± 28.5	0.0	[0 - 33.3]	
Diarrhoea	10 ± 15.3	0.0	[0 - 25]	10 ± 21.3	0.0	[0 - 0]	
Fatigue	35.4 ± 28	44.4	[5.6 - 50]	28.3 ± 25.2	22.2	[5.6 - 38.9]	
Insomnia	30.3 ± 33.2	33.3	[0 - 50]	33.3 ± 37.6	33.3	[0 - 50]	
Constipation	23.3 ± 30	16.7	[0 - 33.3]	13.3 ± 22.1	0.0	[0 - 25]	
Nausea and vomiting	3 ± 6.4	0.0	[0 - 0]	4.5 ± 10.3	0.0	[0 - 0]	
Appetite loss	12.1 ± 16	0.0	[0 - 33.3]	9.1 ± 20.6	0.0	[0 - 0]	
Dyspnoea	6.1 ± 12.9	0.0	[0 - 0]	18.2 ± 26.1	0.0	[0 - 33.3]	
Financial difficulties	24.2 ± 32.1	0.0	[0 - 33.3]	9.1 ± 20.6	0.0	[0 - 0]	
EORTC QLQ-PR25							
Urinary symptoms	36.4 ± 19	33.3	[23.8 - 57.1]	35.9 ± 23.3	42.9	[14.3 - 52.4]	
Incontinence aid	15.2 ± 16.6	0.0	[0 - 33.3]	30.3 ± 36.1	0.0	[0 - 66.7]	
Bowel symptoms	17.5 ± 16.4	20.8	[0 - 25]	16.7 ± 19	12.5	[2.1 - 22.9]	
Hormone treatment- related symptoms	20.3 ± 22.9	16.7	[0 - 26.7]	11.7 ± 14.9	6.7	[0 - 18.3]	
Sexual activity	75 ± 26.4	83.3	[58.3 - 100]	54.2 ± 28.6	33.3	[33.3 - 75]	
Sexual functioning	58.3 ± 8.3	58.3	[54.2 - 62.5]	62.5 ± 4.2	62.5	[60.4 - 64.6]	

TABLE S8. Quality of Life Scores according to EORTC QLQ-C30 and prostate-cancer specific QLQ-PR25 12 months after radiotherapy.

Abbreviations: SD, standard deviation; IQR, interquartile range; PBRT, proton beam therapy; IMRT, intensity-modulated radiotherapy.

TABLE S9. Comparison of results of the present study and a study by Gray et al. [1] regarding quality of life symptoms in bowel and urinary domains. At the top of the table, baseline values are given. Below, differences at 3 and 12 months after treatment compared to the baseline values are presented. On the right side, these changes are compared between IMRT and PBT for the present study.

			S	tudy by G	iray et al. [1]]			Present study								
		PBT				IN	IRT		PBT IMRT								
Questionnaire		P	CSI*			EF	PIC		EC	ORTC-QL	Q-PR25*	ĸ	EC	ORTC-QL	Q-PR25*		-
	Mean	Score	SD		Mean	Score	SD		Mea	n Score	SD		Mea	n Score	SD		-
Baseline																	-
Bowel symptoms		95.1	6.7			94.3	10.9			97.2	7.1			95.8	8.0		
Urinary symptoms	_	78.4	11.0			86.4	14.4			75.6	17.2			76.0	14.4		_
	Mean score change		_	Mean change	Mean score change		_	Mean change	Mean score change			Mean change	Mean score change			Mean change	
	from baseline	SD	p- value†	>0.5 SD	from baseline	SD	p- value†	>0.5 SD	from baseline	SD	p- value [‡]	>0.5 SD	from baseline	SD	p- value [‡]	>0.5 SD	p-value [#] (IMRT vs PBT)
3 months after RT																	
Bowel symptoms	-1.7	8.3	0.062	-	-16.0	21.4	<0.001	+	-4.8	9.5	0.19	+	-9.5	12.2	0.068	+	0.30
Urinary symptoms	-4.8	13.8	0.002	-	-16.5	19.9	<0.001	+	-4.7	15.2	0.29	-	-11.9	16.9	0.012	+	0.09
12 months after RT																	
Bowel symptoms	-6.4	13.2	<0.001	+	-6.3	16.2	<0.001	+	-25.0	29.7	0.11	+	-16.7	20.4	0.18	+	0.38
Urinary symptoms	-6.0	16.9	0.002	+	0.9	15.8	0.52	-	-9.1	19.6	0.26	+	-16.0	19.8	0.036	+	0.19

Abbreviations: EORTC-QLQ-PR25, prostate-cancer specific questionnaire from the European Organisation for Research and Treatment of Cancer; EPIC, Expanded Prostate Cancer Index Composite; IMRT, intenstity-modulated radiotherapy; PBT, proton beam therapy; PCSI, Prostate Cancer Symptom Indices; RT, radiotherapy; SD, standard deviation

* The PCSI and EORTC symptom scales were inverted so that low values represent low symptoms on a linear scale ranging from 0 to 100. Thus, the three instruments are comparable.

[‡]Wilcoxon test

Wilcoxon test

Mann-Whitney U test

[1] Gray PJ, Paly JJ, Yeap BY, et al. Patient-Reported Outcomes After 3-Dimensional Conformal, Intensity-Modulated, or Proton Beam Radiotherapy for Localized Prostate Cancer. Cancer 2013;119:10.1002/cncr.27956




Figure S1. Development of absolute quality of life (QoL) scores of the EORTC-C30 items on the functional scale. High scores represent high/healthy level of functioning or global health status. Numbers above the boxplots represent the number of complete pairs at this time point. RT, radiotherapy; m, months.




Figure S2. Development of absolute quality of life (QoL) scores of the EORTC-C30 items on the symptom scale. High scores represent high level of symptomatology or problems. Numbers above the boxplots represent the number of complete pairs at this time point. RT, radiotherapy; m, months.




Figure S3. Development of absolute quality of life (QoL) scores of the prostate-cancer specific EORTC-PR25 items on the symptom scale. High scores represent high level of symptomatology or problems. Numbers above the boxplots represent the number of complete pairs at this time point. RT, radiotherapy; m, months.




Figure S4. Differences in the absolute quality of life (QoL) scores of the EORTC-C30 items on the functional scale between scores 3 months (3 m, top) and 12 months (12 m, bottom) after radiotherapy (RT) and at baseline. Positive score differences represent an improvement in functioning or global health status. Each patient is represented by a gray dot.




Figure S5. Differences in the absolute quality of life (QoL) scores of the EORTC-C30 items on the symptom scale between scores 3 months (3 m, top) and 12 months (12 m, bottom) after radiotherapy (RT) and at baseline. Positive score differences represent a worsening in symptomatology. Each patient is represented by a gray dot.




Figure S6. Differences in the absolute quality of life (QoL) scores of the EORTC-PR25 items on the symptom scale between scores 3 months (3 m, top) and 12 months (12 m, bottom) after radiotherapy (RT) and at baseline. Positive score differences represent a worsening in symptomatology. Each patient is represented by a gray dot.